Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria (Q80592644)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

Julia Lewis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Nephrology

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

476-477

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0562

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0562

7 January 2021

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0562

7 January 2021

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0562

7 January 2021

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0562

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0562

7 January 2021

Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0562

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0562

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17622227%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference